Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.71 |
| ▸ | CHRM3 | P20309 | 14/20 | 0.53 |
| ▸ | PDE4A | P27815 | 12/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421504 | 0.83 | PDE10A (0.94) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL30068006 | 0.82 | PDE10A (0.48) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL26647253 | 0.82 | PDE10A (0.48) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL26975112 | 0.80 | PDE10A (0.43) | PDE10ACHRM4 | |
| SCHEMBL26975097 | 0.79 | PDE10A (0.75) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL30067796 | 0.77 | PDE10A (0.41) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL26647451 | 0.77 | PDE10A (0.41) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL4432266 | 0.76 | PDE10A (0.69) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL26795649 | 0.75 | CHRM3 (0.40) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL4422798 | 0.75 | PDE10A (0.68) | PDE10ACHRM3PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858915-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | PDE10A 2023/4885CHRM3 4863/4885PDE4A 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.